Gut–brain and brain–gut axis in Parkinson's disease models: Effects of a uridine and fish oil diet

Nutritional Neuroscience

Volumn 21, Issue 6, 2018, Pages 391-402

  Perez Pardo, Paula ^a   Dodiya, Hemraj B ^b   Broersen, Laus M ^a,c   Douna, Hidde ^a   van Wijk, Nick ^c   Lopes da Silva, Sofia ^c   Garssen, Johan ^a,c   Keshavarzian, Ali ^a,b   Kraneveld, Aletta D ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Nutricia Research   (Netherlands)

Author keywords

Docosahexaenoic acid; GI dysfunction; Gut brain and brain gut axis; Rotenone Parkinson's model; Uridine

Indexed keywords

ALPHA SYNUCLEIN; DOCOSAHEXAENOIC ACID; FISH OIL; NEUROTOXIN; PROTEIN ZO1; ROTENONE; URIDINE;

ANATOMICAL CONCEPTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN GUT AXIS; CELL LOSS; COLITIS; CONTROLLED STUDY; DIET; DIGESTIVE SYSTEM FUNCTION DISORDER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; GUT BRAIN AXIS; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MORTALITY; MOTOR FUNCTION TEST; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOTAXIC SURGERY; ANIMAL; BLOOD; BRAIN; C57BL MOUSE; DRUG EFFECT; GASTROINTESTINAL TRACT; METABOLISM; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DIET; DOCOSAHEXAENOIC ACIDS; FISH OILS; GASTROINTESTINAL TRACT; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; ROTENONE; URIDINE;

EID: 85014657418     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1080/1028415X.2017.1294555     Document Type: Article

References (62)

1. Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006 Dec;21(12):2062–7. doi: 10.1002/mds.21076
2. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004 Aug;56(2):173–81. doi: 10.1002/ana.20160
3. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003 Feb;2(2):107–16. doi: 10.1016/S1474-4422(03)00307-7
4. Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2015 Jun;14(6):625–39. doi: 10.1016/S1474-4422(15)00007-1
5. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001 Aug 14;57(3):456–62. doi: 10.1212/WNL.57.3.456
6. Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. Am J Epidemiol 2011 Sep 1;174(5):546–51. doi: 10.1093/aje/kwr119
7. Chen H, Zhao EJ, Zhang W, Lu Y, Liu R, Huang X, et al. Meta-analyses on prevalence of selected Parkinson's nonmotor symptoms before and after diagnosis. Transl Neurodegener 2015;4(1):1. doi: 10.1186/2047-9158-4-1
8. Ponsen MM, Stoffers D, Twisk JWR, Wolters EC, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord 2009 May 15;24(7):1060–5. doi: 10.1002/mds.22534
9. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, Pal A, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012;2:898. doi: 10.1038/srep00898
10. Clairembault T, Leclair-Visonneau L, Neunlist M, Derkinderen P. Enteric glial cells: new players in Parkinson's disease? Mov Disord 2015 Apr;30(4):494–8. doi: 10.1002/mds.25979
11. Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nat Rev Neurol 2015 Nov;11(11):625–36. doi: 10.1038/nrneurol.2015.197
12. Felice VD, Quigley EM, Sullivan AM, O'Keeffe GW, O'Mahony SM. Microbiota-gut-brain signalling in Parkinson's disease: implications for non-motor symptoms. Parkinsonism Relat Disord 2016 Jun;27:1–8. doi: 10.1016/j.parkreldis.2016.03.012
13. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012 Oct;13(10):701–12. doi: 10.1038/nrn3346
14. Miwa H, Kubo T, Suzuki A, Kondo T. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats. Neurosci Lett 2006 Jun 19;401(1–2):146–9. doi: 10.1016/j.neulet.2006.03.003
15. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 2009 Oct;36(1):96–102. doi: 10.1016/j.nbd.2009.06.017
16. Murakami S, Miyazaki I, Sogawa N, Miyoshi K, Asanuma M. Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice. Neurotox Res 2014 Oct;26(3):285–98. doi: 10.1007/s12640-014-9480-1
17. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PloS One 2010;5(1):e8762. doi: 10.1371/journal.pone.0008762
18. Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim J-H, et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006 May;22(2):404–20. doi: 10.1016/j.nbd.2005.12.003
19. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003 Jan;179(1):9–16. doi: 10.1006/exnr.2002.8072
20. Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology 2015 Jan;46:101–16. doi: 10.1016/j.neuro.2014.12.002
21. Greene JG, Noorian AR, Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp Neurol 2009 Jul;218(1):154–61. doi: 10.1016/j.expneurol.2009.04.023
22. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011 Jun;119(6):866–72. doi: 10.1289/ehp.1002839
23. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006 Mar 20;396(1):67–72. doi: 10.1016/j.neulet.2005.11.012
24. Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012 May;27(6):709–15. doi: 10.1002/mds.23838
25. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007 Dec;33(6):599–614. doi: 10.1111/j.1365-2990.2007.00874.x
26. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010 Feb;16(2):79–84. doi: 10.1016/j.parkreldis.2009.08.007
27. Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ. Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci Res 2008 Nov;62(3):206–9. doi: 10.1016/j.neures.2008.07.005
28. Holguin S, Huang Y, Liu J, Wurtman R. Chronic administration of DHA and UMP improves the impaired memory of environmentally impoverished rats. Behav Brain Res 2008 Aug 5;191(1):11–6. doi: 10.1016/j.bbr.2008.02.042
29. Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, et al. Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat Disord 2014 Jan;20(1):82–7. doi: 10.1016/j.parkreldis.2013.09.023
30. Bousquet M, Saint-Pierre M, Julien C, Salem N, Cicchetti F, Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J 2008 Apr;22(4):1213–25. doi: 10.1096/fj.07-9677com
31. Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, et al. Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Med 2005;6(2–3):87–92. doi: 10.1385/NMM:6:2-3:087
32. Delattre AM, Kiss A, Szawka RE, Anselmo-Franci JA, Bagatini PB, Xavier LL, et al. Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease. Neurosci Res 2010 Mar;66(3):256–64. doi: 10.1016/j.neures.2009.11.006
33. Myers CS, Fisher H, Wagner GC. Uridine reduces rotation induced by L-dopa and methamphetamine in 6-OHDA-treated rats. Pharmacol Biochem Behav 1995 Dec;52(4):749–53. doi: 10.1016/0091-3057(95)00169-W
34. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004 Apr;75(4):637–9. doi: 10.1136/jnnp.2003.020982
35. Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, et al. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007 Jun;101(6):1491–504. doi: 10.1111/j.1471-4159.2006.04440.x
36. Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993 Nov;123(11):1939–51. doi: 10.1093/jn/123.11.1939
37. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991 Dec;231(4):482–97. doi: 10.1002/ar.1092310411
38. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Møller A, Nielsen K, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988 May;96(5):379–94. doi: 10.1111/j.1699-0463.1988.tb05320.x
39. Axelsson LG, Landström E, Bylund-Fellenius AC. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment Pharmacol Ther 1998 Sep;12(9):925–34. doi: 10.1046/j.1365-2036.1998.00357.x
40. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci 2009 Jul;1170:615–22. doi: 10.1111/j.1749-6632.2009.04365.x
41. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol (Berl) 2014 Dec;128(6):805–20. doi: 10.1007/s00401-014-1343-6
42. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, et al. Vagotomy and Subsequent Risk of Parkinson's Disease. Ann Neurol 2015 May;78(4):522–9. doi: 10.1002/ana.24448
43. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PloS One 2011;6(12):e28032. doi: 10.1371/journal.pone.0028032
44. Balda MS, Matter K. Tight junctions at a glance. J Cell Sci 2008 Nov 15;121(Pt 22):3677–82. doi: 10.1242/jcs.023887
45. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007 Jun 1;140(1):12–9. doi: 10.1016/j.jss.2006.07.050
46. Maes M, Kubera M, Leunis J-C. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008 Feb;29(1):117–24.
47. Pellegrini C, Fornai M, Colucci R, Tirotta E, Blandini F, Levandis G, et al. Alteration of colonic excitatory tachykinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. J Neuroinflammation 2016;13(1):735. doi: 10.1186/s12974-016-0608-5
48. Mulcahy P, Walsh S, Paucard A, Rea K, Dowd E. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone. Neuroscience 2011 May 5;181:234–42. doi: 10.1016/j.neuroscience.2011.01.038
49. Carriere CH, Kang NH, Niles LP. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease. Neuroscience 2014 May 16;267:114–21. doi: 10.1016/j.neuroscience.2014.02.028
50. Abdel-Salam OE, Khadrawy Y, Youness E, Mohammed N, Abdel-Rahman R, Hussein J, et al. Effect of a single intrastriatal rotenone injection on oxidative stress and neurodegeneration in the rat brain. Comp Clin Pathol 2014;23(5):1457–67. doi: 10.1007/s00580-013-1807-4
51. Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, et al. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 2015 Oct;82:185–99. doi: 10.1016/j.nbd.2015.06.003
52. Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson's disease. J Neurol Sci 2011 Nov 15;310(1–2):12–6. doi: 10.1016/j.jns.2011.05.006
53. Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, MacPhee G, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Movement Disorders 2007 Aug 15;22(11):1623–9. doi: 10.1002/mds.21586
54. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2011 Jan;17(1):10–5. doi: 10.1016/j.parkreldis.2010.08.003
55. Wurtman RJ, Cansev M, Sakamoto T, Ulus I. Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev 2010 Dec;68(Suppl 2):S88–S101. doi: 10.1111/j.1753-4887.2010.00344.x
56. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 2007 Nov 28;1182:50–9. doi: 10.1016/j.brainres.2007.08.089
57. Cansev M, van Wijk N, Turkyilmaz M, Orhan F, Sijben JWC, Broersen LM. A specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. Neurobiol Aging 2015 Jan;36(1):344–51. doi: 10.1016/j.neurobiolaging.2014.07.021
58. van Wijk N, Broersen LM, de Wilde MC, Hageman RJJ, Groenendijk M, Sijben JWC, et al. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. J Alzheimers Dis 2014;38(3):459–79.
59. Zerbi V, Jansen D, Wiesmann M, Fang X, Broersen LM, Veltien A, et al. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. Neurobiol Aging 2014 Mar;35(3):600–13. doi: 10.1016/j.neurobiolaging.2013.09.038
60. Wiesmann M, Zerbi V, Jansen D, Haast R, Lütjohann D, Broersen LM, et al. A dietary treatment improves cerebral blood flow and brain connectivity in aging apoE4 Mice. Neural Plast 2016;2016:6846721. doi: 10.1155/2016/6846721
61. Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 2009 Jan;34(1):55–65. doi: 10.1007/s11064-008-9656-2
62. Cersosimo MG, Benarroch EE. Autonomic involvement in Parkinson's disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers. J Neurol Sci 2012 Feb 15;313(1–2):57–63. doi: 10.1016/j.jns.2011.09.030